BioCentury
ARTICLE | Clinical News

MyoKardia's mavacamten meets in low-dose cohort of Phase II for cardiomyopathy

March 16, 2018 4:42 PM UTC

MyoKardia Inc. (NASDAQ:MYOK) reported data from the 10 patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) in the second cohort of the open-label, U.S. Phase II PIONEER-HCM trial showing that lower doses of oral mavacamten met the primary and several secondary endpoints. The company said the data and data from the first cohort will inform the starting dose and guide dose-adjustment in the Phase III EXPLORER-HCM trial of mavacamten in the indication, which is expected to start next quarter.

Patients in the trial’s second cohort were allowed to use background beta blockers and received once-daily oral mavacamten at a starting dose of 2 mg for weeks 1-4 before increasing to 5 mg for weeks 5-12. The lower doses of mavacamten met the primary endpoint of reducing mean post-exercise left ventricular outflow tract (LVOT) gradient at week 12 compared to baseline (improvement of 25 mmHg, p=0.02). Nine of ten patients in the cohort used beta blockers...